GWGail L. Woods

Gail L. Woods

*This is an algorithmically generated author record based on publicly available information.

Gail L. Woods has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contributors

    by Naif Z. Abraham, Yoshihiro Ashihara, Katalin Banki, Sylva Bem, Jonathan Ben-Ezra, Martin H. Bluth, Jay L. Bock, Dorota Borawski, Michael J. Borowitz, Wilbur B. Bowne, et al.

  • Open Access

    Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data

    by Richard M. Gesser, Kathleen McCarroll, Hedy Teppler, Gail L. Woods

    Objective: The efficacy of ertapenem, 1 g once a day, for treatment of adults with serious infections caused by Enterobacteriaceae was compared with ceftriaxone 1 g once a day [complicated urinary tract infection (CUTI) and community-acquired pneumonia (CAP)] or piperacillin–tazobactam, 3.375 g every 6 h (complicated intra-abdominal, complicated skin/skin structure and acute pelvic infections). Patients and methods: This combined analysis included the subgroup of all 1167 treated patients infected with Enterobacteriaceae from seven randomized double-blind studies. Results: Escherichia coli was the most common pathogen, accounting for 65.3% of all Enterobacteriaceae. Among evaluable patients with deep tissue (intra-abdominal, skin and pelvic) infections, the combined clinical cure rates were 84.8% (223 of 263) for ertapenem and 82.9% (194 of 234) for piperacillin–tazobactam [95% confidence interval (CI) for the difference, adjusting for infection, –4.9% to 8.9%]. Cure rates by infection for ertapenem and piperacillin–tazobactam, respectively, were: intra-abdominal, 85.1% (143 of 168) and 79.9% (119 of 149); pelvic, 86.8% (46 of 53) and 94% (47 of 50); skin/skin structure, 81% (34 of 42) and 80% (28 of 35). Among patients with CUTI, microbiological cure rates were 90.5% (220 of 243) for ertapenem and 92% (196 of 213) for ceftriaxone (95% CI for the difference, –7.1% to 4.1%). In patients with CAP, clinical cure rates were 95% (19 of 20) for ertapenem and 88.9% (16 of 18) for ceftriaxone. Conclusion: Ertapenem therapy was as effective as either piperacillin–tazobactam or ceftriaxone for serious infections caused by Enterobacteriaceae.


  • Open Access

    Multisite Reproducibility of Results Obtained by Two Broth Dilution Methods for Susceptibility Testing of Mycobacterium avium Complex

    by Gail L. Woods, Natalie Williams-Bouyer, Richard J. Wallace, Barbara A. Brown-Elliott, Frank G. Witebsky, Patricia S. Conville, Marianne Plaunt, Geraldine Hall, Priscilla Aralar, Clark Inderlied

    A multicenter study was conducted to assess the interlaboratory reproducibility of susceptibility testing of Mycobacterium avium complex (MAC) by broth microdilution using two different media (cation-adjusted Mueller-Hinton broth with 5% oleic acid-albumin-dextrose-catalase and 7H9 broth with casein) and by macrodilution using the BACTEC 460TB and 12B media at pH 6.8 and 7.3 to 7.4. Ten well-characterized strains of MAC (four macrolide susceptible, six macrolide resistant) were tested against clarithromycin and azithromycin (the latter only by BACTEC 460TB, pH 6.8). At each site, strains were tested against clarithromycin three times on each of three separate days (nine testing events per isolate) by using a common lot of microdilution trays and BACTEC 12B medium, pH 6.8; strains were tested once on three separate days against clarithromycin in 12B medium at pH 7.3 to 7.4 and against azithromycin. Agreement among MICs (i.e., mode ± 1 twofold dilution) was 100% for all strains and both drugs when BACTEC 460TB was used, regardless of the pH of the medium, but varied when microdilution with either medium was used, particularly with susceptible strains. Agreement based on interpretive category, with NCCLS-recommended breakpoints, was 100% for all strains with the BACTEC 460TB method (both drugs and both pH values) and with microdilution using 7H9 broth. With microdilution and Mueller-Hinton broth, agreement by interpretive category was 100% for eight isolates and >90% for two; errors occurred only in laboratories where personnel had minimal experience with this technique. MAC susceptibility testing may be performed by broth macrodilution or microdilution at either pH, with NCCLS-recommended interpretive breakpoints. However, because visual interpretation of broth microdilution end points is subjective, it is more prone to reader error; therefore, this method requires greater expertise than the BACTEC 460TB. Both techniques require appropriate validation and continued documentation of proficiency.


  • Open Access

    Ertapenem Once a Day Versus Piperacillin–Tazobactam Every6 Hours for Treatment of Acute Pelvic Infections:A Prospective, Multicenter, Randomized, Double‐Blind Study

    by Subir Roy, Iliana Higareda, Edith Angel-Muller, Mahmoud Ismail, Caren Hague, Ben Adeyi, Gail L. Woods, Hedy Teppler

    Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute pelvic infections.Methods: In a multicenter, double‐blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin–tazobactam, 3.375 g every 6 hours, both administered intravenously.Results: In total, 163 patients in the ertapenem group and 153 patients in the piperacillin–tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug‐related adverse events were generally similar in both groups.Conclusions: In this study, ertapenem was as effective as piperacillin–tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin–tazobactam.


  • Open Access

    Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection

    by Barbara A. Pelak, Diane M. Citron, Mary Motyl, Ellie J. C. Goldstein, Gail L. Woods, Hedy Teppler

    This study compared the in vitro activities of ertapenem, ceftriaxone, co-amoxiclav, ciprofloxacin and piperacillin–tazobactam against 314 aerobic bacteria and of ertapenem, piperacillin–tazobactam, cefoxitin, ceftriaxone, chloramphenicol, ticarcillin–clavulanate, ampicillin–sulbactam, clindamycin and metronidazole against 500 anaerobic bacteria from 212 patients with acute pelvic infection. Antimicrobial susceptibilities were determined by broth microdilution (aerobes) or agar dilution (anaerobes), following NCCLS guidelines. The most common isolates were Enterobacteriaceae and Peptostreptococcus spp. Ertapenem was the most active drug tested against Enterobacteriaceae (100% susceptible) and anaerobes (99.8% susceptible); the least active agents were co-amoxiclav (79% of Enterobacteriaceae susceptible) and ceftriaxone (85.9% of anaerobes susceptible). All agents tested had excellent activity against β-haemolytic streptococci and methicillin-susceptible Staphylococcus aureus.